These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 25691612)

  • 1. Esophageal and esophagogastric junction cancers, version 1.2015.
    Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
    J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Corvera C; Das P; Denlinger CS; Enzinger PC; Fanta P; Farjah F; Gerdes H; Gibson M; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Johung KL; Keswani RN; Kleinberg LR; Leong S; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Paluri RK; Park H; Perry KA; Pimiento J; Poultsides GA; Roses R; Strong VE; Wiesner G; Willett CG; Wright CD; McMillian NR; Pluchino LA
    J Natl Compr Canc Netw; 2019 Jul; 17(7):855-883. PubMed ID: 31319389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
    Ajani JA; D'Amico TA; Bentrem DJ; Cooke D; Corvera C; Das P; Enzinger PC; Enzler T; Farjah F; Gerdes H; Gibson M; Grierson P; Hofstetter WL; Ilson DH; Jalal S; Keswani RN; Kim S; Kleinberg LR; Klempner S; Lacy J; Licciardi F; Ly QP; Matkowskyj KA; McNamara M; Miller A; Mukherjee S; Mulcahy MF; Outlaw D; Perry KA; Pimiento J; Poultsides GA; Reznik S; Roses RE; Strong VE; Su S; Wang HL; Wiesner G; Willett CG; Yakoub D; Yoon H; McMillian NR; Pluchino LA
    J Natl Compr Canc Netw; 2023 Apr; 21(4):393-422. PubMed ID: 37015332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third international conference of the European Union Network of Excellence on gastric and esophagogastric junction cancer, Cologne, Germany, June 2012.
    Moenig SP; Meyer HJ; Allum WH; De Manzoni G; Garofalo A; Baltin CT; Fetzner UK; Hoelscher AH
    Gastric Cancer; 2015 Jan; 18(1):193-9. PubMed ID: 24522716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
    Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
    Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
    Al-Batran SE; Lorenzen S
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment approaches to esophagogastric junction tumors.
    Kurokawa Y; Sasako M; Doki Y
    Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
    Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
    Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
    Sandler S
    Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences].
    Gockel I; Lordick F; Lyros O; Kreuser N; Hölscher AH; Wittekind C
    Chirurg; 2020 Jan; 91(1):41-50. PubMed ID: 31372677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
    Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
    Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?
    Gronnier C; Piessen G; Mariette C
    J Visc Surg; 2012 Feb; 149(1):e23-33. PubMed ID: 22341763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGJ and esophageal cancers: choosing induction therapy so as to err on the side of overtreatment rather than undertreatment when staging is imperfect.
    Meyers BF; Samson PP
    Oncology (Williston Park); 2014 Jun; 28(6):512, 519-20. PubMed ID: 25134326
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer of the esophagogastric junction.
    Stein HJ; Feith M; Siewert JR
    Surg Oncol; 2000 Jul; 9(1):35-41. PubMed ID: 11525305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
    Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
    Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multimodality therapy for adenocarcinoma of the esophagogastric junction].
    He J; Huang JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Sep; 15(9):877-80. PubMed ID: 22990915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
    Wilke H; Lordick F; Meyer HJ; Stahl M
    Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction.
    Pera M
    Recent Results Cancer Res; 2000; 155():1-14. PubMed ID: 10693234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.